Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Compound Class: Research Peptide
Purity Grade: ≥99% (HPLC Verified)
Appearance: Lyophilized white powder
Formulation: Research-grade lyophilized preparation
Storage Conditions: Store at -20°C, desiccated, protected from light
Solubility: Soluble in bacteriostatic water
Stability: Maintained under recommended storage conditions
Research Use: Intended strictly for laboratory and analytical research purposes
Handling Precautions: Research use only — Not for human consumption
CJC-1295 No DAC, also referred to as Modified GRF 1-29, is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It is designed to stimulate the natural pulsatile release of growth hormone from the pituitary gland while maintaining a shorter active duration compared to DAC-modified versions.
Laboratory research involving CJC-1295 No DAC has focused on its potential effects on growth hormone signaling, IGF-1 production, recovery pathways, metabolic function, and body composition. Due to its short half-life, it is commonly utilized in research models requiring controlled and physiologic-style growth hormone pulse stimulation.
CJC-1295 No DAC is also frequently studied alongside growth hormone secretagogues such as Ipamorelin in investigations involving muscle recovery, sleep quality, tissue repair, and metabolic regulation. Its rapid clearance profile and predictable signaling characteristics make it a valuable compound in peptide and endocrine research applications.
Compound Class: Research Peptide
Purity Grade: ≥99% (HPLC Verified)
Appearance: Lyophilized white powder
Formulation: Research-grade lyophilized preparation
Storage Conditions: Store at -20°C, desiccated, protected from light
Solubility: Soluble in bacteriostatic water
Stability: Maintained under recommended storage conditions
Research Use: Intended strictly for laboratory and analytical research purposes
Handling Precautions: Research use only — Not for human consumption
CJC-1295 No DAC, also referred to as Modified GRF 1-29, is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It is designed to stimulate the natural pulsatile release of growth hormone from the pituitary gland while maintaining a shorter active duration compared to DAC-modified versions.
Laboratory research involving CJC-1295 No DAC has focused on its potential effects on growth hormone signaling, IGF-1 production, recovery pathways, metabolic function, and body composition. Due to its short half-life, it is commonly utilized in research models requiring controlled and physiologic-style growth hormone pulse stimulation.
CJC-1295 No DAC is also frequently studied alongside growth hormone secretagogues such as Ipamorelin in investigations involving muscle recovery, sleep quality, tissue repair, and metabolic regulation. Its rapid clearance profile and predictable signaling characteristics make it a valuable compound in peptide and endocrine research applications.